Chugai Pharmaceutical Co., Ltd. (CHGCF)
OTCMKTS
· Delayed Price · Currency is USD
58.95
+0.29 (0.49%)
At close: Mar 6, 2026
Chugai Pharmaceutical Revenue
In the year 2025, Chugai Pharmaceutical had annual revenue of 1.26T JPY with 7.46% growth. Chugai Pharmaceutical had revenue of 343.50B in the quarter ending December 31, 2025, with 13.71% growth.
Revenue
1,257.94B JPY
Revenue Growth
+7.46%
P/S Ratio
12.34
Revenue / Employee
159.80M JPY
Employees
7,872
Market Cap
98.98B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,257.94B | 87.33B | 7.46% |
| Dec 31, 2024 | 1,170.61B | 59.24B | 5.33% |
| Dec 31, 2023 | 1,111.37B | -148.58B | -11.79% |
| Dec 31, 2022 | 1,259.95B | 260.19B | 26.02% |
| Dec 31, 2021 | 999.76B | 212.81B | 27.04% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 140.12M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| Tian'an Technology Group | 2.12M |
| Vaxart | 148.20M |
Chugai Pharmaceutical News
- 4 weeks ago - Japanese drugmakers slump after Trump unveils discount drug website - Reuters